Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study E1499

  • Mitchell R. Smith
  • , Hailun Li
  • , Leo Gordon
  • , Randy D. Gascoyne
  • , Elisabeth Paietta
  • , Andres Forero-Torres
  • , Brad S. Kahl
  • , Ranjana Advani
  • , Fangxin Hong
  • , Sandra J. Horning

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study E1499'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology